Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Most Lexapro (escitalopram) side effects such as nausea, headache, drowsiness, insomnia, dizziness, and increased sweating start within the first few days and typically fade within 1 to 4 weeks as your body adjusts, though timelines vary by person and dose. Certain effects, including sexual side effects, appetite or weight changes, and emotional blunting, can linger well beyond the first month, and each dose increase may restart a short adjustment window. Some symptoms are not part of normal adjustment at all, including worsening anxiety or agitation, new or increasing suicidal thoughts, and signs of serotonin syndrome, which need prompt medical attention. There are several important factors that affect how long your side effects will last, so see below to understand more before deciding whether to wait it out or contact your prescriber.
If you are unsure whether what you are feeling is a normal adjustment phase or something that needs attention now, a free, instant, online symptom check can help you organize your symptoms, understand possible causes, and see clear next steps in just a few minutes, all before your next appointment.
Last reviewed for medical accuracy: 09/13/2026
How Long Do Lexapro Side Effects Last After Starting?
Lexapro (escitalopram) is a commonly prescribed selective serotonin reuptake inhibitor (SSRI) used to treat depression and anxiety. As with most antidepressants, it can cause side effects—especially during the first few days or weeks of treatment. Understanding what to expect and how long these side effects last can help you stick with your medication and talk more confidently with your doctor.
First 1–2 days
Days 3–7
Weeks 2–4
Weeks 4–6 and beyond
Most side effects occur early and fade over time. Here are the ones you’re most likely to notice:
Most people find these effects are mild or moderate and improve within 1–4 weeks. If they persist beyond six weeks, it’s time to discuss adjustments with your doctor.
Lexapro increases serotonin levels in your brain, which helps regulate mood. However, serotonin also affects other body systems:
Your body gradually adapts to these changes, which is why many side effects fade.
While waiting for side effects to ease, you can try:
Always follow your doctor’s guidance on dosing. Never split or crush pills unless instructed.
If you’re not seeing improvements after six weeks—or if side effects worsen—talk to your prescriber about alternative doses or medications.
Lexapro is generally safe, but rare serious reactions can occur. Contact a doctor or go to an emergency room if you experience:
Never ignore these symptoms. If you’re uncertain, it’s always safer to get evaluated.
Keeping a simple side-effect journal can help you and your doctor see patterns:
If you’re feeling unsure about what you’re experiencing, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
It’s common to feel impatient when side effects kick in. But remember:
Most lexapro side effects begin within days of starting treatment and improve significantly by four to six weeks. Persistent or severe symptoms deserve prompt medical attention. Always discuss any concerns with your doctor—especially if you experience serious or life-threatening reactions.
If you’re ever unsure about what you’re feeling, try a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Speak to a doctor about any side effects that worry you or could be life threatening. Your health and safety come first.
(References)
* Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Ruaño G, Mueller DJ, Tsermpini EE, Brown JT, Bell GC, Leeder JS, Gaedigk A, Scott SA, Klein TE, Caudle KE, Bishop JR. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023 Jul;114(1):51-68. doi: 10.1002/cpt.2903. Epub 2023 May 30. PMID: 37032427; PMCID: PMC10564324.
* Strawn JR, Mills JA, Poweleit EA, Ramsey LB, Croarkin PE. Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents. Pharmacotherapy. 2023 Jul;43(7):675-690. doi: 10.1002/phar.2767. Epub 2023 Jan 27. PMID: 36651686; PMCID: PMC10378577.
* Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, Kaye AD, Viswanath O, Urits I, Boyer AG, Cornett EM, Kaye AM. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurol Int. 2021 Aug 5;13(3):387-401. doi: 10.3390/neurolint13030038. Epub 2021 Aug 5. PMID: 34449705; PMCID: PMC8395812.
* Brown JT, Eum S, Cook EH, Bishop JR. Pharmacogenomics of autism spectrum disorder. Pharmacogenomics. 2017 Mar;18(4):403-414. doi: 10.2217/pgs-2016-0167. Epub 2017 Feb 22. PMID: 28244813.
* MacGregor EA. Migraine, menopause and hormone replacement therapy. Post Reprod Health. 2018 Mar;24(1):11-18. doi: 10.1177/2053369117731172. Epub 2017 Oct 10. PMID: 28994639.
* Sepúlveda-Lizcano L, Arenas-Villamizar VV, Jaimes-Duarte EB, García-Pacheco H, Paredes CS, Bermúdez V, Rivera-Porras D. Metabolic Adverse Effects of Psychotropic Drug Therapy: A Systematic Review. Eur J Investig Health Psychol Educ. 2023 Aug 12;13(8):1505-1520. doi: 10.3390/ejihpe13080110. Epub 2023 Aug 12. PMID: 37623307; PMCID: PMC10453914.
* Prabhakar D, Sablaban I. Escitalopram-Induced Rash. Prim Care Companion CNS Disord. 2019 Jan 31;21(1). doi: 10.4088/PCC.18l02302. Epub 2019 Jan 31. PMID: 30806996.
* Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, De Ronchi D, Fanelli G, Serretti A. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Jul 13;109:110266. doi: 10.1016/j.pnpbp.2021.110266. Epub 2021 Feb 5. PMID: 33549697.
* Conde SL, Nazha H, Simpkins C. Escitalopram Induced Angioedema. Cureus. 2022 Nov;14(11):e31600. doi: 10.7759/cureus.31600. Epub 2022 Nov 17. PMID: 36540519; PMCID: PMC9758958.
* Rissardo JP, Fornari Caprara AL, Bhal N, Repudi R, Zlatin L, Walker IM. Drug-Induced Myoclonus: A Systematic Review. Medicina (Kaunas). 2025 Jan 15;61(1). doi: 10.3390/medicina61010131. Epub 2025 Jan 15. PMID: 39859113; PMCID: PMC11767161.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.